Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schecter

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
Current Medical Research and Opinion|July 14, 2021
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myelomaTom Martin, Saad Z Usmani, Jordan M Schecter, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 28, 2022
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple MyelomaKatja Weisel, Amrita Krishnan, Jordan M Schecter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2022
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)Jian-Qing Mi, Wanhong Zhao, Hongmei Jing, et al.
Ejhaem|July 18, 2022
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myelomaThomas Martin, Amrita Krishnan, Kwee Yong, et al.
Haematologica|June 22, 2019
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studiesMaria-Victoria Mateos, Andrew Spencer, Ajay K Nooka, et al.
The Lancet. Oncology|June 4, 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 10, 2022
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 StudyAdam D Cohen, Parameswaran Hari, Myo Htut, et al.
Haematologica|December 22, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practiceMaria-Victoria Mateos, Katja Weisel, Thomas Martin, et al.
Advances in Therapy|August 6, 2025
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple MyelomaCyrille Touzeau, Brea Lipe, Abdullah M Khan, et al.
Journal of Patient-Reported Outcomes|March 13, 2026
Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trialRoberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Current Medical Research and Opinion|July 14, 2021
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myelomaTom Martin, Saad Z Usmani, Jordan M Schecter, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 28, 2022
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple MyelomaKatja Weisel, Amrita Krishnan, Jordan M Schecter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2022
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)Jian-Qing Mi, Wanhong Zhao, Hongmei Jing, et al.
Ejhaem|July 18, 2022
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myelomaThomas Martin, Amrita Krishnan, Kwee Yong, et al.
Haematologica|June 22, 2019
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studiesMaria-Victoria Mateos, Andrew Spencer, Ajay K Nooka, et al.
The Lancet. Oncology|June 4, 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 10, 2022
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 StudyAdam D Cohen, Parameswaran Hari, Myo Htut, et al.
Haematologica|December 22, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practiceMaria-Victoria Mateos, Katja Weisel, Thomas Martin, et al.
Advances in Therapy|August 6, 2025
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple MyelomaCyrille Touzeau, Brea Lipe, Abdullah M Khan, et al.
Journal of Patient-Reported Outcomes|March 13, 2026
Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trialRoberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.
Pageof 8